BiotechTV | All Videos

1 day ago

Marianne De Backer talks about joining Vir Biotechnology and shares her vision for the future

Vir's new CEO gives an overview of the company's programs and discusses future plans to expand into autoimmune disease and oncology.

Alto Neuroscience's CEO on why MDD data at #ACNP2023 may validate its precision medicine approach

2 days ago

Company News

Alto Neuroscience's CEO on why MDD data at #ACNP2023 may validate its precision medicine approach

Amit Etkin says that psychiatric conditions have been treated too broadly in the past.

Mapping autism spectrum disorder protein interactions with the director of UCSF's QBI

2 days ago

Bright Minds

Mapping autism spectrum disorder protein interactions with the director of UCSF's QBI

Nevan Krogan, Director of the Quantitative Biosciences Institute at UCSF, expands on work posted to bioRxiv today.

William Blair Senior Biotech Analyst Andy Hsieh joins Analyst Thursdays from the Bay Area

6 days ago

Bright Minds

William Blair Senior Biotech Analyst Andy Hsieh joins Analyst Thursdays from the Bay Area

Andy Hsieh comments on AbbVie's buyout of ImmunoGen, gives a deep dive into radiopharmaceutical, and discusses AASLD, Seagen, and Icosavax.

SR One's Simeon George on recent news from CRISPR, Turning Point (Bristol), Arcellx, and more

Nov 22

Bright Minds

SR One's Simeon George on recent news from CRISPR, Turning Point (Bristol), Arcellx, and more

Simeon George talks about his firm's philosophy, advice for biotech entrepreneurs, and discusses a busy few weeks of news.

BridgeBio's Neil Kumar reviews #AHA23 data and the company's pipeline and finances

Nov 21

Company News

BridgeBio's Neil Kumar reviews #AHA23 data and the company's pipeline and finances

Neil Kumar discusses the competitive profile he sees emerging for acoramidis, a big phase 3 in ADH1 and investing in early science.

Sofinnova Investments' Jakob Dupont on the private markets in biotech

Nov 20

Bright Minds

Sofinnova Investments' Jakob Dupont on the private markets in biotech

Jakob Dupont says he is focused on clinical stage companies or ones that are months within IND.

Checking in with Cytokinetics ahead of the SEQUOIA-HCM P3 study result due in December

Nov 20

Company News

Checking in with Cytokinetics ahead of the SEQUOIA-HCM P3 study result due in December

President and CEO Robert Blum describes aficamten's mechanism, the trial's study design, and reflects on Cytokinetics' 25 years.

Next generation T-cell engineering with ArsenalBio

Nov 20

Tech + Tours

Next generation T-cell engineering with ArsenalBio

Co-founder, Chairman & CEO Ken Drazan explains the array of applications that Arsenal engineers into its CAR-T cells.

BMO's Evan Seigerman joins Analyst Thursdays from London

Nov 16

Bright Minds

BMO's Evan Seigerman joins Analyst Thursdays from London

Evan Seigerman discusses news from #AHA23, what's going on with Structure, Verve's polarizing result, Neurocrine, Vertex, Pfizer and more.

An exclusive look at the Cellares Cell Shuttle automated cell therapy manufacturing system

Nov 15

Tech + Tours

An exclusive look at the Cellares Cell Shuttle automated cell therapy manufacturing system

CEO Fabian Gerlinghaus shares a business overview and VP of R&D Daniele Malleo gives a hands on tour of how the Cell Shuttle works.

Stifel's Paul Matteis joins BiotechTV for Analyst Thursdays

Nov 9

Bright Minds

Stifel's Paul Matteis joins BiotechTV for Analyst Thursdays

Paul Matteis comments on Biogen and Vertex earnings, discusses recent news on BioMarin and Sage.

PHIOGEN's CEO explains the concept of using phages against drug-resistant bacteria

Nov 7

Bright Minds

PHIOGEN's CEO explains the concept of using phages against drug-resistant bacteria

Amanda Burkhardt describes how phages selectively target bacteria of interest and how PHIOGEN's platform is designed for broad spectrum.

An AI expert describes how machine learning is changing drug development

Nov 7

Bright Minds

An AI expert describes how machine learning is changing drug development

Angela Holmes explains how her company uses computational power to help companies with drug development.

The CEO of NKILT Therapeutics talks about using NK cells to target the HLA-G pathway

Nov 7

Bright Minds

The CEO of NKILT Therapeutics talks about using NK cells to target the HLA-G pathway

Raphaël Ognar discusses the results we have seen in the NK space over recent years.

Tvardi Threrapeutics' CEO on targeting STAT3

Nov 7

Bright Minds

Tvardi Threrapeutics' CEO on targeting STAT3

Imran Alibhai describes how Tvardi is taking the approach of using a non-covalent inhibitor to prevent the activation of STAT3.

Everything drug developers need to know about CPRIT oncology grants

Nov 7

Bright Minds

Everything drug developers need to know about CPRIT oncology grants

CPRIT Deputy Executive Officer and General Counsel Kristen Doyle explains the details of this Texas cancer research funding program.

UTMB's President discusses his institution, and comments on the chronic kidney disease field

Nov 7

Bright Minds

UTMB's President discusses his institution, and comments on the chronic kidney disease field

Jochen Reiser talks about the reach of UTMB and the science happening in Galveston, and highlights immunology approaches to kidney disease.

The director of Rice's Biotech Launchpad describes technologies that are being turned into companies

Nov 7

Bright Minds

The director of Rice's Biotech Launchpad describes technologies that are being turned into companies

Omid Veiseh explains the idea behind Rice's Biotech Launchpad, describes the cytokine company Avenge Bio, and talks about other technologies

Texas Medical Center's CEO talks about Houston's new TMC Helix Park

Nov 7

Bright Minds

Texas Medical Center's CEO talks about Houston's new TMC Helix Park

Bill McKeon describes TMC's news campus that is focused on translational research.

Home

BiotechTV U

Company News

Bright Minds

Tech + Tours

Follow BiotechTV

Sponsors

Popular

Get in Touch

Advertise:

News coverage opportunities:

Advertise@BiotechTV.com

MediaOppty@BiotechTV.com

General equiries and feedback:

BiotechTV U:

Info@BiotechTV.com

Universities@BiotechTV.com

Contributors

Brad Loncar

Founder

Join our mail list

Disclosures & Policies